Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella
Open Access
- 1 January 2009
- journal article
- Published by Springer Nature in Journal of Immune Based Therapies and Vaccines
- Vol. 7 (1) , 1
Abstract
There is no safe, effective human vaccine against brucellosis. Live attenuated Brucella strains are widely used to vaccinate animals. However these live Brucella vaccines can cause disease and are unsafe for humans. Killed Brucella or subunit vaccines are not effective in eliciting long term protection. In this study, we evaluate an approach using a live, non-pathogenic bacteria (E. coli) genetically engineered to mimic the brucellae pathway of infection and present antigens for an appropriate cytolitic T cell response.Keywords
This publication has 80 references indexed in Scilit:
- Host Immune Responses to the Intracellular Bacteria Brucella: Does the Bacteria Instruct the Host to Facilitate Chronic Infection?Critical Reviews in Immunology, 2006
- Laboratory Exposures to Brucellae and Implications for BioterrorismEmerging Infectious Diseases, 2005
- BrucellosisNew England Journal of Medicine, 2005
- From the discovery of the Malta fever?s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosisVeterinary Research, 2005
- Infections émergentes ou ré-émergentes utilisables pour le bioterrorismeLa Presse Médicale, 2005
- Bioterrorism and the nervous systemCurrent Neurology and Neuroscience Reports, 2003
- Bacterial Agents Used for BioterrorismSurgical Infections, 2003
- Brucellosis.2003
- Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and HumansClinical Microbiology Reviews, 2003
- Human brucellosis.2002